^
    1d
    Palmitoylation modification of SPI1 promotes nasopharyngeal carcinoma radioresistance through inhibiting c-CBL-mediated ubiquitination and degradation. (PubMed, Drug Resist Updat)
    Collectively, our findings suggest that SPI1 palmitoylation inhibits c-CBL-mediated ubiquitination and degradation, thereby enhancing SPI1 protein stability and its transcriptional regulation of miR-205-5p. Upregulated miR-205-5p in NPC cells is packaged into exosomes and transferred to endothelial cells, where it targets and inhibits WWC2 expression, eventually promoting angiogenesis and NPC radioresistance.
    Journal
    |
    SPI1 (Spi-1 Proto-Oncogene) • WWP2 (WW Domain Containing E3 Ubiquitin Protein Ligase 2) • MIR205 (MicroRNA 205)
    3d
    Clinicopathological and molecular genetic characteristics of Epstein-Barr virus-positive small cell neuroendocrine carcinoma of the nasopharynx. (PubMed, Histopathology)
    This largest integrated study defines the distinct clinicopathological and molecular profile of EBV-positive SCNEC-nasopharynx. The identified diagnostic immunophenotype and potential oncogenic pathways provide a foundation for precise diagnosis and future targeted therapy development.
    Journal • Tumor mutational burden
    |
    EGFR (Epidermal growth factor receptor) • TMB (Tumor Mutational Burden) • SYP (Synaptophysin)
    4d
    Comprehensive Characterization of Stem Cell Landscape Identifies Novel Stemness-Relevant Genes for Nasopharyngeal Carcinoma Therapy. (PubMed, Cancers (Basel))
    This study systematically characterized two NPC subtypes with distinct stemness features, clinical outcomes, and TIME features. Novel stemness-related markers will provide valuable targets against metastatic or recurrent NPC.
    Journal • IO biomarker
    |
    CDC45 (Cell Division Cycle 45)
    5d
    Inhibition of radiotherapy sensitivity in nasopharyngeal carcinoma via the long non-coding RNA RHPN1-AS1. (PubMed, Transl Cancer Res)
    This study confirmed that RHPN1-AS1 expression inhibits the radiosensitivity of NPC cells. RHPN1-AS1 may affect NPC radiotherapy sensitivity by targeting CELF2 to regulate the MAPK pathway.
    Journal
    |
    CELF2 (CUGBP Elav-Like Family Member 2) • TP53BP1 (Tumor Protein P53 Binding Protein 1) • RHPN1-AS1 (RHPN1 Antisense RNA 1)
    5d
    Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors (clinicaltrials.gov)
    P2, N=314, Recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Feb 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CD4 (CD4 Molecule)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar)
    6d
    Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC) (clinicaltrials.gov)
    P2, N=24, Recruiting, Stanford University | Trial completion date: Dec 2027 --> Jan 2029 | Trial primary completion date: Dec 2025 --> Jan 2029
    Trial completion date • Trial primary completion date
    |
    cisplatin • gemcitabine • docetaxel • Loqtorzi (toripalimab-tpzi) • capecitabine
    6d
    CROSSROAD: Treatment Regimen Switch - Re-induction Chemotherapy vs. Direct Radiotherapy in LANPC With Inadequate Response to Induction Chemotherapy (clinicaltrials.gov)
    P=N/A, N=223, Not yet recruiting, Fujian Cancer Hospital
    New trial
    7d
    CD38 degrades MAVS through mitophagy to inhibit type I interferon secretion in nasopharyngeal carcinoma cells and impairs CD8+T cell-mediated anti-tumor immunity. (PubMed, Nat Commun)
    Importantly, CD38 promotes tumor progression and reduces the proportion of CD8+T cells and IFNγ+CD8+T cells in vivo via MAVS. In conclusion, these findings reveal previously unrecognized roles and mechanisms of CD38 in regulating anti-tumor T cell immunity, suggesting that inhibition of CD38 could initiate tumor-targeted immune responses, enhance anti-tumor immunity in patients, and provide new therapeutic strategies for NPC.
    Journal
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma)
    8d
    Lactoferrin inhibits anoikis-resistance and metastasis of nasopharyngeal carcinoma cells via the AKT signaling pathway. (PubMed, Int J Clin Exp Pathol)
    Our study revealed that LTF inhibits anoikis-resistance and metastasis of NPC cells via the AKT signaling pathway.
    Journal
    |
    NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • CDH1 (Cadherin 1) • VIM (Vimentin) • MMP9 (Matrix metallopeptidase 9)
    9d
    Neutrophils in nasopharyngeal carcinoma: from mechanisms to therapeutics. (PubMed, J Transl Med)
    This review establishes a unifying framework linking EBV-driven inflammation to neutrophil plasticity, NET biology, and NPC progression. Neutrophils are dynamic, targetable components with dual pro-tumor and anti-tumor roles. While neutrophil-related indices hold prognostic value, their clinical translation requires standardization and integration with other biomarkers. Targeting suppressive neutrophil programs and NETs offers promising strategies to improve therapeutic efficacy and overcome treatment resistance in NPC.
    Review • Journal • IO biomarker
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8) • CXCR1 (Chemokine (C-X-C motif) receptor 1)
    10d
    A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma (clinicaltrials.gov)
    P2, N=238, Active, not recruiting, Shanghai Miracogen Inc. | Recruiting --> Active, not recruiting | Trial completion date: Feb 2025 --> Dec 2026
    Enrollment closed • Trial completion date
    |
    docetaxel • capecitabine • Meiyouheng (becotatug vedotin)